The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.60
Bid: 18.60
Ask: 18.98
Change: -0.07 (-0.37%)
Spread: 0.38 (2.043%)
Open: 20.00
High: 20.00
Low: 18.60
Prev. Close: 18.86
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nanoco and Merck Sign Agreement

1 Aug 2016 07:00

RNS Number : 7626F
Nanoco Group PLC
01 August 2016
 

For immediate release

1 August 2016

 

 

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

 

Nanoco and Merck Sign Agreement on

Eco-Friendly Quantum Materials for Displays

 

 

· Cadmium-free quantum dots enable ultra-bright displays with a substantially extended colour range

· Nanoco enters into a non-exclusive licence agreement with Merck, which will market Nanoco's material to its broad customer base in the display industry

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, and Merck, a leading science and technology company, today announced the signing of a worldwide material supply and licensing agreement. The licence allows Merck to immediately start marketing Nanoco's cadmium-free quantum dots and to ultimately establish its own production facility to meet growing market demand.

"The agreement is in line with Merck's strategy to sustainably secure its position as the global market and technology leader in display materials. With cadmium-free quantum dots a remarkable increase in the colour range and a significant reduction in power consumption can be achieved. These cadmium-free quantum dots are eco-friendly and also complement our product portfolio for the display industry," said Walter Galinat, member of the Merck Executive Board and CEO of Performance Materials. "The licence agreement with Nanoco will strengthen our position in quantum materials research, for which we laid the foundations by acquiring Qlight Nanotech of Israel last year."

The financial details of the agreement are not being disclosed, but Nanoco will receive a licence fee and royalties on Merck's sales of the Nanoco cadmium-free quantum dots Merck manufactures. In line with Nanoco's commercialisation strategy in the display market, this agreement is non-exclusive. Merck will begin marketing Nanoco's technology in the near term by selling cadmium-free quantum dots manufactured at Nanoco's expanded production plant in Runcorn, UK. The licence allows Merck to establish its own production facility for cadmium-free quantum dots in line with global market demand at a later point in time. Michael Edelman, Nanoco's Chief Executive Officer, added: "This agreement with Merck is another major endorsement of the world-class quality of our cadmium free quantum dot technology. We are convinced that Merck can leverage its position in the display industry with these innovative materials."

Advantages of quantum materials

Quantum materials offer a substantial additional benefit when they are used as color converters in the light source of liquid crystal displays. In conventional displays, the colors blue, green, and red are filtered out of the original white light of the LED light source. A great deal of light is lost in this process. Because a blue LED in combination with red and green quantum materials only generates the blue, green and red light that is perfectly transmitted through the filters, there is much less absorption. This increases the display's brightness, reduces electricity consumption and leads to much purer and potentially stronger colors.

 

This announcement contains inside information.

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

David Blain, Chief Financial Officer

Caroline Watson, Investor Relations Manager

cwatson@nanocotechnologies.com

 

Tel: + 44 (0) 7799 897357

Canaccord Genuity - Joint Broker

Tel: +44 (0) 20 7523 8000

Simon Bridges

Cameron Duncan

Richard Andrews

Liberum - Joint Broker

Tel: +44 (0) 20 3100 2000

Neil Patel

Richard Bootle

Steven Tredget

Buchanan

Tel: +44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Stephanie Watson

 

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LC displays, lighting, solar cells and bio-imaging. In the display market, Nanoco has non-exclusive manufacturing and marketing licensing agreements with The Dow Chemical Company and Taiwan's Wah Hong Industrial Corporation. Nanoco also has a strategy of direct sales in display and in its other target markets, including lighting.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Greater China. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

 

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKMGFNGMFGVZZ
Date   Source Headline
1st Aug 20196:15 pmRNSHolding(s) in Company
31st Jul 20197:00 amRNSContract Liability Waived
3rd Jul 20195:50 pmRNSHolding(s) in Company
27th Jun 201912:15 pmRNSHolding(s) in Company
26th Jun 20193:20 pmRNSDirector/PDMR Shareholding
26th Jun 201911:45 amRNSHolding(s) in Company
25th Jun 201912:45 pmRNSHolding(s) in Company
24th Jun 20193:45 pmRNSHolding(s) in Company
24th Jun 20193:30 pmRNSHolding(s) in Company
24th Jun 20193:30 pmRNSHolding(s) in Company
21st Jun 20197:00 amRNSUS Customer partnership update
12th Jun 201910:25 amRNSBlock listing Interim Review
7th Jun 20194:00 pmRNSDirector/PDMR Shareholding
3rd May 20197:00 amRNSDirector/PDMR Shareholding
2nd May 20196:09 pmRNSDirector/PDMR Shareholding
18th Apr 20194:55 pmRNSDirector/PDMR Shareholding
17th Apr 20193:20 pmRNSHolding(s) in Company
17th Apr 20191:22 pmRNSHolding(s) in Company
16th Apr 20195:08 pmRNSHolding(s) in Company
11th Apr 20193:38 pmRNSHolding(s) in Company
11th Apr 20197:00 amRNSDirector/PDMR Shareholding
9th Apr 20197:00 amRNSInterim Results
1st Apr 201911:40 amRNSHolding(s) in Company
12th Mar 20197:00 amRNSDirectorate Changes
4th Mar 20197:00 amRNSNotice of Results
31st Jan 20197:00 amRNSChange of Auditor
25th Jan 20197:00 amRNSContract extension signed
4th Jan 201912:18 pmRNSHolding(s) in Company
4th Jan 20197:00 amRNSPartnership with Plessey Semiconductors
24th Dec 20187:00 amRNSMilestone Achieved
13th Dec 20183:33 pmRNSResult of AGM
13th Dec 20187:00 amRNSAGM Statement
10th Dec 20184:00 pmRNSBLOCKLISTING SIX-MONTHLY RETURN
3rd Dec 201811:18 amRNSDirector Declaration
3rd Dec 20187:00 amRNSHolding(s) in Company
30th Nov 20184:35 pmRNSPrice Monitoring Extension
16th Nov 20184:53 pmRNSHolding(s) in Company
15th Nov 20187:00 amRNSDirector/PDMR Shareholding
13th Nov 20188:15 amRNSAnnual Report and Notice of AGM
7th Nov 20181:33 pmRNSDirector/PDMR Shareholding
24th Oct 20187:00 amRNSHolding(s) in Company
17th Oct 20181:47 pmRNSDirector/PDMR Shareholding
16th Oct 201811:14 amRNSDirector/PDMR Shareholding
16th Oct 20187:00 amRNSPreliminary Results
3rd Oct 20187:00 amRNSHolding(s) in Company
24th Sep 20185:00 pmRNSHolding(s) in Company
17th Sep 20187:00 amRNSHolding(s) in Company
17th Sep 20187:00 amRNSHolding(s) in Company
11th Sep 20187:00 amRNSInvestor day
5th Sep 20182:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.